KalVista Pharmaceuticals/$KALV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About KalVista Pharmaceuticals
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Ticker
$KALV
Sector
Primary listing
Employees
270
Headquarters
Website
KALV Metrics
BasicAdvanced
$708M
-
-$3.95
-0.10
-
Price and volume
Market cap
$708M
Beta
-0.1
52-week high
$17.28
52-week low
$7.30
Average daily volume
902K
Financial strength
Current ratio
5.365
Quick ratio
4.989
Long term debt to equity
334.249
Total debt to equity
334.249
Interest coverage (TTM)
-21.79%
Profitability
EBITDA (TTM)
-201.82
Gross margin (TTM)
-4,166.97%
Net profit margin (TTM)
-14,242.43%
Operating margin (TTM)
-14,220.83%
Effective tax rate (TTM)
-2.81%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-60.98%
Return on equity (TTM)
-190.18%
Valuation
Price to revenue (TTM)
505.667
Price to book
17.29
Price to tangible book (TTM)
17.29
Price to free cash flow (TTM)
-4.28
Free cash flow yield (TTM)
-23.36%
Free cash flow per share (TTM)
-3.273
Growth
Earnings per share change (TTM)
10.62%
3-year earnings per share growth (CAGR)
2.70%
What the Analysts think about KALV
Analyst ratings (Buy, Hold, Sell) for KalVista Pharmaceuticals stock.
Bulls say / Bears say
The FDA approved Ekterly (sebetralstat) on July 7, 2025 as the first oral on-demand HAE therapy, driving a >17% premarket share jump and positioning KalVista for peak U.S. sales of ~$250 million according to Citizens Bank (Reuters)
The FDA’s extension of the PDUFA review was attributed solely to heavy workload, with no requests for additional data or safety concerns raised, underscoring regulator confidence in sebetralstat’s efficacy and safety profile (Reuters)
KalVista’s launch funding plan includes an at-the-market equity program for up to $100 million, ensuring financial flexibility to support Ekterly commercialization and operations into 2027 (Reuters)
The FDA missed its June 17 PDUFA goal date for sebetralstat, delaying approval by at least four weeks due to agency resource constraints, highlighting regulatory unpredictability for KalVista’s lead product (Reuters)
Ekterly is expected to be priced slightly higher than Takeda’s Firazyr ($11,000 per dose), potentially constraining market adoption in a cost-sensitive rare-disease segment (Reuters)
KalVista’s filing of an at-the-market equity program for up to $100 million to fund commercialization could lead to significant share dilution, dampening shareholder returns (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
KALV Financial Performance
Revenues and expenses
KALV Earnings Performance
Company profitability
KALV News
AllArticlesVideos
KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results
Business Wire3 days ago
KalVista Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Benzinga4 days ago
KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025
Business Wire1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for KalVista Pharmaceuticals stock?
KalVista Pharmaceuticals (KALV) has a market cap of $708M as of September 14, 2025.
What is the P/E ratio for KalVista Pharmaceuticals stock?
The price to earnings (P/E) ratio for KalVista Pharmaceuticals (KALV) stock is 0 as of September 14, 2025.
Does KalVista Pharmaceuticals stock pay dividends?
No, KalVista Pharmaceuticals (KALV) stock does not pay dividends to its shareholders as of September 14, 2025.
When is the next KalVista Pharmaceuticals dividend payment date?
KalVista Pharmaceuticals (KALV) stock does not pay dividends to its shareholders.
What is the beta indicator for KalVista Pharmaceuticals?
KalVista Pharmaceuticals (KALV) has a beta rating of -0.1. This means that it has an inverse relation to market volatility.